Senseonics (NYSE:SENS) today announced preliminary revenues for the third quarter and plans to conduct a reverse stock split. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker expects approximately $8.1 million in revenue for the third quarter of 2025. That marks a 91% uptick from the third quarter of 2024. The company attributed its growth […]
Wall Street Beat
Analysts label Embecta ‘undervalued’ and poised for growth
BTIG analysts maintain a “Buy” rating for Embecta (Nasdaq:EMBC) after meetings with company officials highlighted plans for growth. Marie Thibault, Sam Eiber and Alexandra Pang hosted Embecta CEO Devdatt Kurdikar and Head of Investor Relations Pravesh Khandelwal this week. Following the in-person and virtual meetings, the analysts maintain confidence in the former BD Diabetes unit’s […]
Vivani sets date for neuromod spin-off as focus turns to drug delivery implant
Vivani Medical (Nasdaq:VANI) announced today that it set a record date for the approved spin-off of its Cortigent subsidiary. In May, the Alameda, California-based company announced plans to spin off Cortigent, its division developing brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic […]
Court dismisses several claims against Dexcom in securities lawsuit
A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts. Judge Robert S. Huie of the Southern District of California ruled in the consolidated action, which combines three securities class actions against the San Diego-based continuous glucose monitor (CGM) maker. Huie’s judgment denied Dexcom’s motion to dismiss […]
Medtronic says MiniMed separation remains on track, next-gen pump submissions on the way
Medtronic (NYSE:MDT) officials today said that the company’s planned separation of its Diabetes business is on the right track. The medtech giant announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. […]
Embecta stock gets a boost on Q3 beats, raised guidance
Embecta (Nasdaq:EMBC) shares ticked up today on third-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of EMBC 17% to $12.12 apiece in early-morning trading today. The Parsippany, New Jersey-based diabetes technology company — which spun off from BD three years ago — reported profits of $45.5 million. That equals […]
Insulet increases 2025 guidance on Q2 beats, 33% sales growth
Insulet (Nasdaq:PODD) shares ticked up before hours today on second-quarter results that came in ahead of the consensus forecast. Shares of PODD rose 13% to $$313.45 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $22.5 million. That equals 32¢ per share on sales of $649.1 million for […]
Senseonics posts Street-beating Q2 with 37% sales growth
Senseonics (NYSE:SENS) shares remained relatively unmoved today on second-quarter results that beat the consensus sales forecast. Shares of SENS rose 1% to 49¢ apiece in post-market trading after the earnings release on Wednesday, Aug. 6. They fell 8% to 45¢ apiece in mid-morning the next day. The Germantown, Maryland-based long-term implantable CGM maker reported losses […]
Tandem Diabetes Care posts Q2 sales beat, expects $1B in revenue for 2025
Tandem Diabetes Care (Nasdaq:TNDM) shares fell after hours today on second-quarter results that topped the consensus sales forecast. Shares of TNDM fell 14% to $12.40 apiece in post-market trading after the release of the earnings on Wednesday, Aug. 6. Today, they are down 26.3% to $10.60 apiece. The San Diego-based automated insulin delivery technology developer […]
MannKind submits inhaled insulin to FDA for pediatrics, inks $500M financing agreement with Blackstone
MannKind (Nasdaq:MNKD) today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said. First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin […]
